Cyclopamine
Cyclopamine (11-deoxojervine) is a naturally occurring chemical that belongs in the family of steroidal alkaloids. It is a teratogen isolated from the corn lily ("Veratrum californicum") that causes fatal birth defects. It prevents the embryonic brain from separating into two lobes (an extreme form of holoprosencephaly), which in turn causes the development of a single eye (cyclopia). The chemical was named after this effect, as it was originally noted by Idaho lamb farmers who contacted the US Department of Agriculture after their herds gave birth to cycloptic lambs in 1957. It then took more than a decade to  identify the corn lily as the culprit. Later work suggested that different rain patterns caused the sheep to graze differently, impacting the amount of corn lily ingested by pregnant sheep. The poison interrupts the sonic hedgehog signaling pathway during development, thus causing birth defects. Discovery and naming. In 1957, Idaho sheep ranchers contacted the US Department of Agriculture (USDA) when their sheep gave birth to lambs with a fatal singular eye deformity. After collecting local flora and feeding them to mice, USDA scientists struggled to recreate the cyclopia. After a decade of trial and error, they came across wild corn  lilies and advised the ranchers to avoid the corn lilies. Cyclopamine was one of three steroidal alkaloids isolated from "Veratrum californicum", known also as the California corn lily, but the only unknown at the time, and it was named after its effects on sheep embryos. Four decades later a team led by Professor Phillip Beachy related the sonic hedgehog gene to cyclopamine. Upon experimentation, they recreated cyclopia by silencing the sonic hedgehog gene. Professor Beachy then connected their cycloptic results to the cycloptic sheep noted four decades earlier. Source and structure. The biosynthesis of cyclopamine begins with cholesterol. A steroid  skeleton has a classic 6-member ring, adjacent to another 6, 6, then a five or "6-6-6-5". "Veratrum" was determined to contain five types of alkaloids, each of which had a common cholesterol precursor: (1) solanidine alkaloids, (2) verazine alkaloids, (3) vertramine alkaloids, (4) jervine alkaloids, and (5) the cevanine alkaloids. In biosynthesis, Cyclopamine has a solanide (1) precursor, which itself is made from cholesterol. This was determined by initial studies which isolated alkaloids from corn lily ("Veratrum californium)", and introduced these to embryonic sheep. At the time, jervine was an already known alkaloid which was isolated  from corn lily alongside two other alkaloids: the unknown cyclopamine and veratramine; each with different toxicities. Later studies then demonstrated that jervine degraded to cyclopamine upon a Wolff-Kishner reduction, which helped identify the unknown compound. It was also demonstrated that treatment of cyclopamine with a Lewis acid (pH < 2) leads to the production of veratramine. The stomach provides these conditions, and thus only a small amount of cyclopamine passes through the stomach after ingestion. And even though only a small amount of ingested cyclopamine passes the stomach, it remains unaffected afterwards. Veratramine is highly toxic, even if it  does not impact development, as it excites the central nervous system and can cause seizures – similarly to serotonin. The mechanism for the production of veratramine focuses on the cleavage of a carbon-oxygen bond, which leads to the formation of a new double bond. From there, this ring is almost aromatic. The driving force to become aromatic then pushes an elimination reaction, creating a third double bond and producing aromaticity, as depicted in the figure below. Mechanism. Cyclopamine impacts embryonic development by hindering the sonic hedgehog (Shh) pathway. In healthy development, the Shh gene codes for Shh proteins. These proteins  have a high affinity for a surface membrane protein called "Patched". Upon binding, Shh proteins inhibit Patched. With Patch inhibited, another surface membrane protein called "Smoothened" may signal further cascades which impact development. Cyclopamine has a high affinity for Smoothened – and upon binding, inhibits the signal. Even though Shh may inhibit Patched, Smoothened cannot signal in the presence of Cyclopamine and thus the pathway is interrupted. Embryological. Cyclopamine causes the most advanced form of holoprosencephaly. Because it blocks Shh signaling, the embryonic brain no longer divides into lobes (becomes alobar). Thus, only one optical track develops, hence the cycloptic  (singular) eye. Furthermore, this disease is fatal and presently has no cure. Medical potential. Cyclopamine is currently being investigated as a treatment agent in basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma, tumors that commonly result from excessive SHh activity, glioblastoma, and as a treatment agent for multiple myeloma. For example, studies of epithelial cancers have demonstrated that tumor cells secrete Shh ligand to signal adjacent growth factors production by stromal cells which leads to angiogenesis, tumor cell proliferation, and tumor cell survival. With this in mind, one can imagine cyclopamine as a way of attenuating cancer's mechanism. However, while cyclopamine  has been demonstrated to inhibit tumor growth in mouse xenograft models, it never reached therapeutic potential as it caused many side effects including weight loss, dehydration, and death in mouse models. Having said that, two functional analogs of cyclopamine have been approved by the FDA; vismodegib in 2012, and sonidegib in 2015. Furthermore, vismodegib was the first Shh pathway drug approved for treating cancer. While cyclopamine and vismodegib do not appear very similar, the development of vismodegib revealed which aspects of cyclopamine give it functionality and used those results to make vismodegib. For example, the added chlorine group in Vismodegib  gives the drug a much higher solubility than cyclopamine – low solubility is a hindrance towards making cyclopamine a practical drug. The development of vismodegib revealed structure activity relationships (SAR), and determined that hydrogen bonding in two sites, as well as solubility, impact the effectiveness of the drug. Specifically speaking, the two hydrogen bonds work in opposite ways; at one site a tyrosine residue on the Smoothened receptor offers a proton to be accepted whereas a separate arginine residue works as a hydrogen bond acceptor. While the accepting group is more impactful, having both makes for stronger binding.